Blueprint, Deciphera present Phase I GIST data
Blueprint Medicines Corp. (NASDAQ:BPMC) and Deciphera Pharmaceuticals LLC (Waltham, Mass.) each presented Phase I data Thursday for candidates targeting stem cell factor (SCF) receptor tyrosine kinase (c-KIT; KIT; CD117) and platelet derived growth factor receptor A (PDGFRA; PDGFR2; CD140A) to treat gastrointestinal stromal tumors.
In a Phase I study, Blueprint said BLU-285 produced partial responses (PRs) in seven of 28 patients evaluable at a Nov. 1 data cutoff. Six of 15 patients with PDGFRA-driven GIST had a PR as defined by RECIST criteria, as did one of 13 with a KIT mutation...